Navigation Links
Particle Sciences Completes Development of First Product Incorporating its Unique Surface Modification System
Date:2/24/2009

BETHLEHEM, Pa., Feb. 24 /PRNewswire/ -- Particle Sciences Inc. today announced the development of a unique film-forming system with applications ranging from tissue hydration to the passivation of medical device surfaces. "The backbone of the system is a series of patent-pending polymers that allow Particle Sciences to 'dial in' the desired contact angle," says Andrew Loxley, PS' Director of New Technologies.

Particle Sciences has already used the system to develop an ocular formulation for one of its clients. Early clinical results are very promising but are still embargoed. "In this application, we were able to achieve substantial improvement over existing products in terms of degree and duration of activity using this newly developed approach," says Robert Lee, PS' VP Pharmaceutical Development.

Dr. Lee adds that "This technology adds to the broad array of approaches Particle Sciences has to address our clients' needs. As formulations become increasingly challenging, Particle Sciences has positioned itself well with the development and acquisition of various technologies and capabilities focused on drug delivery."

Particle Sciences is an integrated provider of drug development services. Particle Sciences focuses on emulsions, gels, particulates and drug/device combination products with additional specialized capabilities in topical and mucosal drug delivery. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania. For more information on Particle Sciences, visit www.particlesciences.com.

    Contact:
    Maureen Cochran
    mcochran@particlesciences.com
    610-861-4701


'/>"/>
SOURCE Particle Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
2. Anthrax vaccine produces immunity with nanoparticles, not needles
3. CeloNova BioSciences Announces Worlds First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres
4. New DNA-based technique for assembly of nano- and micro-sized particles
5. New nanoparticle vaccine is more effective but less expensive
6. Anthrax vaccine produces immunity with nanoparticles, not needles
7. Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types
8. Researchers outline structure of largest nonvirus particle ever crystallized
9. DNA technique yields 3-D crystalline organization of nanoparticles
10. Strengthening fluids with nanoparticles
11. 2-faced particles act like tiny submarines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 2016  Soligenix, Inc. (OTCQB: SNGX) (Soligenix or ... developing and commercializing products to treat rare diseases ... today the long-term follow-up data from its Phase ... Innate Defense Regulator (IDR), in the treatment of ... patients undergoing chemoradiation therapy (CRT).  The additional 12-month ...
(Date:12/8/2016)... Fla. , Dec. 8, 2016  HedgePath ... company that discovers, develops and plans to commercialize ... its shares of common stock were approved for ... will begin trading on the OTCQX, effective today, ... qualify for the OTCQX market, companies must meet ...
(Date:12/8/2016)... 2016 Eutilex Co. Ltd. today announced that ... Series A financing. This financing round included participation from ... SNU Bio Angel. This new funding brings the total ... $27.7M) since its founding in 2015. ... and commercialization of its immuno-oncology programs, expand its R&D ...
(Date:12/8/2016)... , Dec. 8, 2016   Biocept, Inc ... commercial provider of clinically actionable liquid biopsy tests ... that clinical data featuring its Target Selectorâ„¢ Circulating ... biopsy for the detection of actionable biomarkers in ... research sponsored by Sara Cannon Research Institute (SCRI), ...
Breaking Biology Technology:
(Date:12/7/2016)... -- According to a new market research report "Emotion Detection and ... Recognition), Service, Application Area, End User, And Region - Global Forecast to 2021", ... Billion in 2016 to USD 36.07 Billion by 2021, at a Compound Annual ... ... MarketsandMarkets Logo ...
(Date:12/6/2016)... Valencell , the leading innovator in ... a third consecutive year of triple digit growth for ... with a 360 percent increase in companies who have ... driven by sales of its wrist and ear Benchmarkâ„¢ ... technology for hearables for fitness and healthcare applications. ...
(Date:11/30/2016)... FRANCISCO and WARSAW, Poland , Nov. 30, 2016 /PRNewswire/ ... It is one of the most crucial aspects of recovery so we need to ... of serious health risks, including heart problems, high blood pressure, stroke, diabetes, and even ... and friends sleep and find a Christmas present that could help them to manage ... ...
Breaking Biology News(10 mins):